Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OS7K
|
|||
| Former ID |
DNCL002501
|
|||
| Drug Name |
EGEN-001
|
|||
| Indication | Fallopian tube cancer [ICD-11: 2C74; ICD-10: C57.0] | Phase 2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [1] | ||
| Peritoneal cancer [ICD-11: 2C51.Z] | Phase 2 | [1] | ||
| Company |
EGEN
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01118052) EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. U.S. National Institutes ofHealth. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 454593). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.